DeepMed Research

ABBVIE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor

Phase 1

Completed

Conditions: Gastric Cancer

Interventions: Drug: Veliparib

First Posted Date: 2010-05-14

Last Posted Date: 2021-08-02

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 60

Registration Number: NCT01123876

Locations: 🇺🇸
Site Reference ID/Investigator# 24986, Washington, District of Columbia, United States
🇺🇸
Site Reference ID/Investigator# 24987, Scottsdale, Arizona, United States
🇺🇸
Site Reference ID/Investigator# 24985, Los Angeles, California, United States

and more 5 locations

A Study to Assess the Effect of Rifampin on the Metabolism of Navitoclax

Phase 1

Completed

Conditions: Lymphoma, Including Chronic Lymphocytic Leukemia
Solid Tumors

Interventions: Drug: navitoclax
Drug: Rifampin

First Posted Date: 2010-05-12

Last Posted Date: 2017-11-21

Lead Sponsor: AbbVie

Target Recruit Count: 12

Registration Number: NCT01121133

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Completed

Conditions: Moderate-to-severe Rheumatoid Arthritis

First Posted Date: 2010-05-05

Last Posted Date: 2016-02-24

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 1013

Registration Number: NCT01117480

A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer

Phase 2

Completed

Conditions: Ovarian Cancer

Interventions: Drug: ABT-888
Drug: pegylated liposomal doxorubicin
Drug: temozolomide

First Posted Date: 2010-04-30

Last Posted Date: 2018-06-06

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 168

Registration Number: NCT01113957

Locations: 🇦🇺
Site Reference ID/Investigator# 25133, Nedlands, Australia
🇺🇸
Site Reference ID/Investigator# 25029, Hilliard, Ohio, United States
🇺🇸
Site Reference ID/Investigator# 25039, Peoria, Illinois, United States

and more 29 locations

Efficacy and Safety of Humira® in Patients With Psoriatic Arthritis in Normal Medical Practice

Completed

Conditions: Psoriatic Arthritis

First Posted Date: 2010-04-27

Last Posted Date: 2014-12-30

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 4635

Registration Number: NCT01111240

Locations: 🇩🇪
Site Reference ID/Investigator# 52995, Berlin, Germany
🇩🇪
Site Reference ID/Investigator# 35549, Berlin, Germany
🇩🇪
Site Reference ID/Investigator# 64288, Aachen, Germany

and more 506 locations

ABT-348 as Monotherapy or Combination With Carboplatin or Docetaxel to Treat Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: ABT-348
Drug: ABT-348 and docetaxel
Drug: ABT-348 and carboplatin

First Posted Date: 2010-04-26

Last Posted Date: 2013-11-06

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 102

Registration Number: NCT01110486

Locations: 🇺🇸
Site Reference ID/Investigator# 26524, Houston, Texas, United States
🇺🇸
Site Reference ID/Investigator# 26525, Chicago, Illinois, United States

ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies

Phase 1

Completed

Conditions: Chronic Myelogenous Leukemia
Myelodysplasia
Acute Lymphoblastic Leukemia
Acute Myelogenous Leukemia
B-cell Chronic Lymphocytic Leukemia

Interventions: Drug: ABT-348
Drug: ABT-348 and azacitidine

First Posted Date: 2010-04-26

Last Posted Date: 2017-11-20

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 52

Registration Number: NCT01110473

Locations: 🇺🇸
Site Reference ID/Investigator# 59324, Scottsdale, Arizona, United States
🇺🇸
Site Reference ID/Investigator# 26523, Atlanta, Georgia, United States
🇺🇸
Site Reference ID/Investigator# 26522, Houston, Texas, United States

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Completed

Conditions: Human Immunodeficiency Virus

First Posted Date: 2010-04-02

Last Posted Date: 2017-05-23

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 3049

Registration Number: NCT01097655

Safety and Efficacy Study for Cognitive Deficits in Adult Subjects With Schizophrenia

Phase 2

Completed

Conditions: Cognitive Deficits in Schizophrenia

Interventions: Drug: ABT-126
Drug: Placebo

First Posted Date: 2010-03-30

Last Posted Date: 2018-06-06

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 207

Registration Number: NCT01095562

Locations: 🇺🇸
Site Reference ID/Investigator# 27072, Tampa, Florida, United States
🇺🇸
Site Reference ID/Investigator# 26264, Torrance, California, United States
🇺🇸
Site Reference ID/Investigator# 27073, New York, New York, United States

and more 20 locations

A 3-year Study Following up Patients With Moderate to Severe Rheumatoid Arthritis Treated With Humira in Greece

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2010-03-12

Last Posted Date: 2013-09-26

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 566

Registration Number: NCT01086033

Locations: 🇬🇷
Site Reference ID/Investigator# 47544, Ag. Dimitrios, Athens, Greece
🇬🇷
Site Reference ID/Investigator# 29953, Athens, Greece
🇬🇷
Site Reference ID/Investigator# 30480, Athens, Greece

and more 57 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy